Market Outlook: Assessing Readiness for the Next IPO Window
February 27, 2024
Biotechnology IPO activity since the 2021 peak is still down more than 70%, tracking with the U.S. Federal Reserve’s lifting of interest rates. As macroeconomic forecasts envision interest rates to start plateauing in the year ahead, IPOs have fewer reasons to delay. This panel will consider the readiness of investors and public markets to increase their support for biomedical innovation as well as explain how the bold companies that have launched this year built their appeal to stand out.
)
){kind=logo}
)
){kind=logo}
){kind=logo}